CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies
L Aragón-Serrano, L Carrillo-Serradell… - International Journal of …, 2023 - mdpi.com
Cancer management still requires more potent and safer treatments, of which
immunomodulatory receptors on the lymphocyte surface have started to show promise in …
immunomodulatory receptors on the lymphocyte surface have started to show promise in …
Ligands of CD6: roles in the pathogenesis and treatment of cancer
M Gurrea-Rubio, F Lin, MS Wicha… - Frontiers in …, 2025 - frontiersin.org
Cluster of Differentiation 6 (CD6), an established marker of T cells, has multiple and complex
functions in regulation of T cell activation and proliferation, and in adhesion of T cells to …
functions in regulation of T cell activation and proliferation, and in adhesion of T cells to …
Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells
M Gurrea-Rubio, Q Wu, MA Amin, PS Tsou… - Cancer Immunology …, 2024 - Springer
Immune checkpoint inhibitors (ICIs) have demonstrated efficacy and improved survival in a
growing number of cancers. Despite their success, ICIs are associated with immune-related …
growing number of cancers. Despite their success, ICIs are associated with immune-related …
Single‐cell RNA‐sequencing and spatial transcriptomic analysis reveal a distinct population of APOE− cells yielding pathological lymph node metastasis in papillary …
G Xiao, R Xie, J Gu, Y Huang, M Ding… - Clinical and …, 2025 - Wiley Online Library
Background Thyroid cancer is one of the most common endocrine tumors worldwide,
especially among women and the metastatic mechanism of papillary thyroid carcinoma …
especially among women and the metastatic mechanism of papillary thyroid carcinoma …
Optimization and Characterization of Novel ALCAM-Targeting Antibody Fragments for Transepithelial Delivery
A Bauer, S Klassa, A Herbst, C Maccioni, W Abhamon… - Pharmaceutics, 2023 - mdpi.com
Activated leukocyte cell adhesion molecule (ALCAM) is a cell adhesion molecule that
supports T cell activation, leukocyte migration, and (lymph) angiogenesis and has been …
supports T cell activation, leukocyte migration, and (lymph) angiogenesis and has been …
Expression of CD6 in aggressive NK/T-cell neoplasms and assessment as a potential therapeutic target: A bone marrow pathology group study
X Zhao, CM McCall, JG Block, SL Ondrejka… - … Myeloma and Leukemia, 2024 - Elsevier
Abstract Background Aggressive NK/T-Cell neoplasms are rare hematological malignancies
characterized by the abnormal proliferation of NK or NK-like T (NK/T) cells. CD6 is a …
characterized by the abnormal proliferation of NK or NK-like T (NK/T) cells. CD6 is a …
Histone methyltransferase DOT1L maintains identity and restricts cytotoxic potential of CD8 T cells
M Malik, WJ de Leeuw, MA Aslam… - bioRxiv, 2025 - biorxiv.org
The histone methyltransferase DOT1L is emerging as a central epigenetic regulator in
immune cells. Loss of DOT1L during development of CD8 T cells in vivo leads to gain of …
immune cells. Loss of DOT1L during development of CD8 T cells in vivo leads to gain of …
Robust senescence evaluation by transcriptome-based hUSI to facilitate characterizing cellular senescence under various conditions
T Ni, J Wang, W Wang, J Yao, X Zhou, G Wei - 2024 - researchsquare.com
Despite the manifestation and contribution of cellular senescence to tissue aging and aging-
related disease, the identification of in vivo senescent cells and the recognition of …
related disease, the identification of in vivo senescent cells and the recognition of …